National Leprosy Eradication Programme (NLEP)Kavya .
Chronic infectious disease caused by Mycobacterium leprae.
It usually affects the skin and peripheral nerves
Long incubation period generally 5-7 years.
Classified as paucibacillary or multibacillary
permanent disability
Timely diagnosis and treatment of cases
Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV). By damaging your immune system, HIV interferes with your body's ability to fight infection and disease.
The National AIDS Control Programme (NACP), launched in 1992, is being implemented as a comprehensive programme for prevention and control of HIV/AIDS in India. Over time, the focus has shifted from raising awareness to behavior change, from a national response to a more decentralized response and to increasing involvement of NGOs and networks of PLHIV.
National Leprosy Eradication Programme (NLEP)Kavya .
Chronic infectious disease caused by Mycobacterium leprae.
It usually affects the skin and peripheral nerves
Long incubation period generally 5-7 years.
Classified as paucibacillary or multibacillary
permanent disability
Timely diagnosis and treatment of cases
Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV). By damaging your immune system, HIV interferes with your body's ability to fight infection and disease.
The National AIDS Control Programme (NACP), launched in 1992, is being implemented as a comprehensive programme for prevention and control of HIV/AIDS in India. Over time, the focus has shifted from raising awareness to behavior change, from a national response to a more decentralized response and to increasing involvement of NGOs and networks of PLHIV.
Dear Doctor,
Its humbling that you liked the presentation and would like to use it for your purpose. Kindly find your requested presentation attached with this email.
The shortlink for your future reference is http://go.drankush.com/PolioFinal
We would always appreciate if you would place this reference as a due credit in your work and while sharing for others use.
Ankush, Amroskar S, Bhamaikar V, Barreto J. "Polio Final Presentation" Accessed from http://go.drankush.com/PolioFinal
-----------------------------------------------------
As we near eradication of this dreaded disease - "POLIO", we would like to share the following presentation we made for our Pediatrics seminar in 2012.
Best attempts have been made to cover most of the topic, keeping the size under 100 slides.
Hope you like it.
Ankush
Shahin Amroskar
Varsha Bhamaikar
Joyce Barreto
Malaria is curable if effective treatment is started early because delay in treatment may lead to serious consequences including death.
Prompt and effective treatment is also important for controlling the transmission of malaria.
A revised National Drug Policy on Malaria has been adopted by the Ministry of Health and Family Welfare, Govt of India in 2010 and these guidelines have been prepared for healthcare personnel involved in the treatment of malaria.
The ppt highlights types of insecticide resistance, resistance towards antimalarials, rationale of National drug policy for malaria, use of GIS in epidemic predictions for kala azar, malaria, genetically modified mosquitoes and malaria vaccine
diagnosis and treatment of malaria according to National Malaria Treatment Protocol Nepal 2019: includes treatment of vivax and falciparum malaria, and chemoprophylaxis
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
2. 1. Management of malaria cases in the
community.
2. Active intervention to control/interrupt
malaria transmission with community
participation.
3. Should be given first priority.
Healthy guides and multipurpose workers are
fully trained to detect and treat malaria cases at
community level with support from referral
system.
Govt have also established drug distribution
centres and fever depot all over the country.
4. National Drug Policy on Malaria was first formulated
in 1982 and has subsequently been reviewed and
revised periodically.
5. Emphasis on complete treatment in diagnosed
cases of malaria rather then one single dose
presumptive treatment to suspect the case of
malaria to avoid choloroquine resistance in
P.falciparum.
The first line of treatment is choloroquine
6. Providing complete cure (clinical and
parasitological) of malaria cases
Prevention of progression of uncomplicated
malaria into severe malaria and thereby
reduce malaria mortality.
Prevention of relapses by administration of
radical treatment
Interruption of transmission of malaria by use
of gametocytocidal drugs
Preventing development of drug resistance
by rational treatment of malaria cases.
7.
8. Avoid starting Rx on empty stomach.,
1st dose given under observation.,
Dose repeated if vomiting within 30 minutes
Patient should report back if no improvement
after 48 hrs.
Patient should be examined for concomitant
illness.
9. All fever cases suspected to be malaria
should be investigated by microscopy or RDT
10. All mixed infections should be treated with
full course of ACT and Primaquine 0.25 mg
per kg body weight daily for 14 days
11. P.vivax cases should be treated with chloroquine
for three days and Primaquine for 14 days
Chloroquine: 25 mg/kg body weight divided over
three days i.e. 10mg/kg on day 1, 10mg/kg on
day 2 and 5mg/kg on day 3.
2. Primaquine: 0.25 mg/kg body weight daily for
14 days.
12. Primaquine is used to prevent relapse.
Contraindicated in pregnant women, infants
and individuals with G6PD deficiency
13. Patients should be instructed to report back
in case of haematuria or high colored urine
/cyanosis or blue coloration of lips and
Primaquine should be stopped in such cases.
Care should be taken in patients with
anaemia
14. Chloroquine first drug of choice
If chloroquine resistant, then Artesunate combined
therapy(ACT)
ACT consists of Artesunate combined with a long
acting antimalarial like sulfadoxine and
pyrimethamine
Artesunate 4 mg/kg body weight daily for 3 days
Sulfadoxine (25 mg/kg body weight) – Pyrimethamine
(1.25 mg/kg body weight) on first day
Primaquine 0.75 mg/Kg body weight on Day 2
18. Choice of antimalarial is quinine injection
10mg/kg body wt.
I.V drip in 5% dextrose saline to be runover 4hrs
Total duration of treatment is of 7 days
Injectable form of artemisinine derivatives
may be used for the management of the
sever complicated malaria in adult and non-
pregnant women only
19. Artesunate
2.4mg/kg bw
IM or IV followed by 1.2mg/kg bw once daily for 4
days
Total duration is 5 days
Artemether
1.6mg/kg bw
IM followed by 1.6mg/kg bw daily for total 6
injection or twice for 3 days
Artether
150mg daily IM for 3 days
Only for adult
Artemisinine
10mg/kg bw at 0 and 4 hours followed by 7mg/kg bw
at 24,36,48 and 60 hours
20. Choloroquine has few side effects like nausea, vomiting,
blurring of vision and headache.
Cases of retinal damage has been reported but only in a
person exposed to large cumulative dose over many years
Choloroquine should not given to empty stomach.
21. Symptoms may be of three types
Plasmocid types
Rare toxic manifestation involving the CNS
Gastrointestinal
Cramps,nausea and vomiting
Cardiovascular
Most serious toxic menifestation
22. It is recommended for highly infected endemic
areas
It is not recommended to children under 5 :
Impossible to achieve continuous suppression in a
significant proportion of the population
Interfere in the development of promotive immunity
May accelerate devlopment of drugs resistance
May increase the risk of retinopathy
23. Chemoprophylaxis should be administered only in selective
groups in high P.falciparum endemic areas.
This is recommended for travelers to endemic
areas,soldiers,police and labour forces working in endemic
areas
Recommendations for dosing are:-
1)dose for children should be based on body weight
2)daily anti malarials should started the day before
travel(eg:-doxycycline)
3)weekly chloroquine started 1 week before arrival
24. Doxycycline: 100 mg once daily for adults
and 1.5 mg/kg once daily for children
(contraindicated in children below 8 years).
The drug should be started 2 days before
travel and continued for 4 weeks after
leaving the malarious area.
25. Mefloquine: 250 mg weekly for adults and
should be administered two weeks
before, during and four weeks after
exposure.
Mefloquine is contraindicated in individuals
with history of convulsions, neuropsychiatric
problems and cardiac conditions.
Therefore, necessary precautions should be
taken and all should undergo screening
before prescription of the drug
26. 1. Stratification of problem
Essential feature for planning and development
of a sound control strategy to maximise
utilization of available resources.
Provide guidelines as to which strategy could
be most suited.
27. Action For individual and
family protection
For community
protection
Reduction of human-
mosquito contact
Insecticide-treated
nets,repellants,protect
ive clothing,screening
of houses.
Insecticide-treated
nets
Zooprophylaxis
Destruction of adult
mosquitoes
Insecticide-treated
nets,indoor residual
spraying,space
spraying
Destruction of
mosquitoe larvae
Peri-domestic
sanitation
Larviciding of water
surfaces,intermittent
irrigation,sluicing
Source reduction Small scale drainage Environmental
sanitation,water
management,drainage
Social participation Motivation for personal
and family protection
Health
education,community
participation
28. 2. Vector control strategy
Anti-adult measures
Residual spray
Spraying indoor surface of house with
DDT/malathion.
Discontinuation lead to resurgence of malaria.
Reduces the longevity of vector.
Space application
Major anti-epidemic measure
Involves application of pestisidesin the form of fug
or mist using special equipments
29. Individual protection
Man-vector contact can be reduced by
Using nets, protecting cloth, coils,
repellents,screening of houses.
30. Anti-larval measure
Larvicides
Oiling the collection of standing water or dusting them
with paris green effectively controlled malaria.
Some moderm larvicides such as temephos which
confer long effect with low toxicity are more widely
used
31. Source reduction
Techniques to reduce mosquito breeding sites drainage or
filling.
Deepening or flushing
Management of water level
Changing the salt content of water
Intermittent irrigation
32. Integrated control
In order to reduce too much dependence
residual insecticides, increasing emphasis is
being put on integrated vector control
methodology which includes bio-environmental
and personal protection measure
33. The Govt of every country affected by malaria has a
National control policy covering prevention and case
management
Objectives are
Ensure rapid cure of infection
Reduce morbidity and mortality, including malarial
related anemia
Prevent the progression of uncomplicated malaria into
severe disease
Reduce the impact of malarial infection on the fetus
during pregnancy
Reduce the reservoir infection
Prevent the emergence and spreading of drug resistance
and prevent malaria in travellers
34. Malaria control added impetus as initiative was
launched by WHO,UNICEF,UNDP and world bank
in 1998 .
Aim:-to reduce the Deaths and incidence To 75% by
2015.
35. Vaccination against malaria is a burning issue
today
Several vaccine candidates are now being
tested in africa, asia and US
A vaccine developed in columbia (SPF 66)
advanced to phase 3 trials in africa but failed
to show efficacy in chiildren under 1
Another vaccine (RTS, S/AS02) with the
potential to prevent infection and ameliorate
disease is being tested by GlaxoSmithKline
and the MVI at PATH in Phase I trial in
Gambia
36. In phase II in 2002 trials of the vaccine are
being conducted among the children in
Mozambique, which suffers from year-round
malaria transmission offering a better
opportunity to evaluate vaccine performance
This vaccine has been safely tested in adult
volunteeers in Belgium, Gambia, kenya and
US
only potential malarial vaccine